Rigel Pharmaceuticals

South San Francisco,  CA 
United States
https://www.rigel.com/

• Booth: 10031a

Rigel's first FDA approved product TAVALISSE® (fostamatinib disodium hexahydrate) tablets, is the only oral spleen tyrosine kinase (SYK) inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. It is now also commercially available in Europe and Canada TAVALISSE is in a Phase 3 clinical trial for the treatment of warm antibody autoimmune hemolytic anemia (AIHA) and a Phase 3 clinical trial for the treatment of hospitalized COVID-19 patients To see the full Prescribing Information visit TAVALISSEhcp.com

Brands: https://events.jspargo.com/ASCO21/CUSTOM/rigel.png

 Show Specials

• TAVALISSE Clinical Data Highlights (Apr 29, 2021)

  https://vimeo.com/542900906/a8c9a40cba

 Press Releases

• TAVALISSE Mechanism of Action (Jun 03, 2021)
  https://tavalissehcp.com/moa

• TAVALISSE HCP Website (Jun 03, 2021)
  https://tavalissehcp.com/ 

• Rigel Pharmaceuticals Website (Jun 03, 2021)
  https://www.rigel.com/

• TAVALISSE Prescribing Information (Jun 03, 2021)
  https://tavalissehcp.com/downloads/pdf/TAVALISSE-Full-Prescribing-Information.pdf

• Rigel Pharmaceuticals Pipeline (Jun 03, 2021)
  https://www.rigel.com/pipeline

 Products